急性冠脉综合征双联抗血小板降阶治疗:个体患者荟萃分析
降阶组1年缺血复合终点(2.3% vs 3.0%,HR 0.761)和出血终点(6.5% vs 9.1%,HR 0.701)均显著低于标准组,全因死亡与大出血无显著差异。
要点
- ACS患者PCI后降阶DAPT较标准DAPT降低1年缺血复合终点和出血终点。
- 非指导性降阶对出血终点的降低幅度显著大于指导性降阶(交互P=0.007)。
- 全因死亡和大出血事件两组间无显著差异。
核心结论
- 在ACS患者中,基于DAPT的降阶策略与缺血复合终点和出血终点均降低相关。
- 出血终点的降低在非指导性降阶策略中比指导性降阶策略更为显著。
研究设计与样本
- 研究类型为个体患者数据荟萃分析,检索PubMed、Embase和Cochrane数据库筛选随机临床试验。
- 共同主要终点为PCI后1年的缺血复合终点(心源性死亡、心肌梗死和脑血管事件复合)和出血终点(任何出血)。
- 研究注册于PROSPERO(ID: CRD42021245477)。
主要发现
- 降阶策略组缺血终点发生率为2.3%,标准策略组为3.0%(HR 0.761,95%CI 0.597-0.972,log rank P=0.029)。
- 降阶策略组出血发生率为6.5%,标准策略组为9.1%(HR 0.701,95%CI 0.606-0.811,log rank P<0.001)。
- 全因死亡和主要出血事件两组间无显著差异。
- 亚组分析显示非指导性降阶较指导性降阶对出血终点降低影响更大(交互P=0.007),缺血终点无组间差异。
临床怎么用
- 对于ACS行PCI的患者,可考虑采用P2Y12抑制剂降阶策略以平衡缺血与出血风险。
- 非指导性降阶策略在减少出血方面可能优于指导性降阶,但需结合患者个体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Dual-antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is the standard treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). De-escalation of the potent P2Y12 inhibtor is an appealing concept to balance the ischaemic and bleeding risks after PCI. An individual patient data meta-analysis was performed to compare de-escalation versus standard DAPT in patients with ACS. METHODS AND RESULTS: Electronic databases, including PubMed, Embase, and the Cochrane database, were searched to identify randomised clinical trials (RCTs) comparing the de-escalation strategy with the standard DAPT after PCI in patients with ACS. Individual patient-level data were collected from the relevant trials. The co-primary endpoints of interest were the ischaemic composite endpoint (a composite of cardiac death, myocardial infarction, and cerebrovascular events) and bleeding endpoint (any bleeding) at 1-year post-PCI. Four RCTs (the TROPICAL-ACS, POPular Genetics, HOST-REDUCE-POLYTECH-ACS, and TALOS-AMI trials) including 10 133 patients were analysed. The ischaemic endpoint was significantly lower in the patients assigned to the de-escalation strategy than in those assigned to the standard strategy (2.3% vs. 3.0%, hazard ratio [HR] 0.761, 95% confidence interval [CI] 0.597-0.972, log rank P = 0.029). Bleeding was also significantly lower in the de-escalation strategy group (6.5% vs. 9.1%, HR 0.701, 95% CI 0.606-0.811, log rank P < 0.001). No significant intergroup differences were observed in terms of all-cause death and major bleeding events. Subgroup analyses revealed that compared to guided de-escalation, unguided de-escalation had a significantly larger impact on bleeding endpoint reduction (P for interaction = 0.007); no intergroup differences were observed for the ischaemic endpoints. CONCLUSION: In this individual patient data meta-analysis, DAPT-based de-escalation was associated with both decreased ischaemic and bleeding endpoints. Reduction in bleeding endpoints was more prominent for the unguided than the guided de-escalation strategy. STUDY REGISTRATION NUMBER: This study was registered in the PROSPERO (ID: CRD42021245477).
引用
- Kang, Rizas, Park, et al. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis. Eur Heart J. 2023. PMID: 36883613. doi:10.1093/eurheartj/ehac829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。